EVOTEC AG (NASDAQ:EVTCY) Evotec SE: Bayer discontinues clinical development candidate eliapixant (BAY1817080), Evotec regains the rights to all P2X3 assets
Transparency directive : regulatory news
|
DGAP-Ad-hoc: Evotec SE / Key word(s): Miscellaneous Hamburg, Germany - Evotec SE (Frankfurt Stock Exchange, MDAX/TecDAX, ISIN: DE 000 566480 9, WKN 566480; NASDAQ) announces today that the Company has been informed by Bayer about a decision to discontinue the development of the investigational P2X3 receptor antagonist eliapixant (BAY1817080), which stems from a former Evotec/Bayer multi-target research alliance. Following a review of the available data, Bayer concluded that the overall benefit no longer outweighs the risk in the actively pursued indications. As a consequence of Bayer's decision, Evotec regains the rights to all P2X3 assets. The Company will evaluate the underlying data as soon as they are made available and will evaluate all options. This decision has no impact on the overall strategic goals as outlined in Action Plan 2025. - End of ad hoc release - Contact: Dr Werner Lanthaler, Chief Executive Officer, Evotec SE, Manfred Eigen Campus, Essener Bogen 7, 22419 Hamburg, Germany, Phone: +49.(0)40.560 81-242, werner.lanthaler@evotec.com
04-Feb-2022 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | Evotec SE |
| Manfred Eigen Campus / Essener Bogen 7 | |
| 22419 Hamburg | |
| Germany | |
| Phone: | +49 (0)40 560 81-0 |
| Fax: | +49 (0)40 560 81-222 |
| E-mail: | info@evotec.com |
| Internet: | www.evotec.com |
| ISIN: | DE0005664809 |
| WKN: | 566480 |
| Indices: | MDAX, TecDAX |
| Listed: | Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Nasdaq |
| EQS News ID: | 1276916 |
| End of Announcement | DGAP News Service |
|
|
1276916 04-Feb-2022 CET/CEST